ADRX.US ADARx Pharmaceuticals, Inc. Common Stock
- Market cap
- USD 1.66B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ADRX.US undervalued?
Graham numberThe Graham number of ADARx Pharmaceuticals, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ADARx Pharmaceuticals, Inc. Common Stock fundamental analysis
No fundamental analysis for ADARx Pharmaceuticals, Inc. Common Stock yet.
ADARx Pharmaceuticals, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ADARx Pharmaceuticals, Inc. Common Stock
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and…
Full company profileADARx Pharmaceuticals, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ADARx Pharmaceuticals, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 3.45M | 5.77M |
| Operating Income | -58.2M | -88.4M | -114M |
| EBITDA | -56.7M | -86.0M | -111M |
| Net Income | -46.4M | -73.1M | -96.9M |
| EPS | -0.45 | -0.72 | -0.95 |
| Balance Sheet | |||
| Total Assets | 233M | 508M | 456M |
| Total Liabilities | 371M | 710M | 707M |
| Shareholders' Equity | -137M | -202M | -251M |
| Cash & Short-term Investments | 14.0M | 66.5M | 58.5M |
| Cash Flow | |||
| Operating Cash Flow | -48.6M | 262M | -99.7M |
| Capital Expenditure | 455K | 2.94M | 888K |
| Free Cash Flow | -49.0M | 259M | -101M |
| Ratios | |||
| ROA | -19.9% | -14.4% | -21.2% |
| Net Profit Margin | - | -2,119.1% | -1,678.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ADARx Pharmaceuticals, Inc. Common Stock dividends
ADARx Pharmaceuticals, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns ADARx Pharmaceuticals, Inc. Common Stock
- Insiders 41.78%
- Institutions 55.99%
- Public & others 2.23%
- Shares outstanding 111M
- Free float 49.4M
Top funds holding ADRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 3.25M | 2.93% | 0.00% | Sep 2026 |
| HBM Healthcare Investments AG Ord | 1.31M | 1.18% | 0.00% | Sep 2026 |
| MFS New Discovery I | 484K | 0.44% | 0.00% | Sep 2026 |
| Fidelity Contrafund | 468K | 0.42% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 466K | 0.42% | 0.00% | Sep 2026 |
| AB Small Cap Growth A | 431K | 0.39% | 0.00% | Sep 2026 |
| AB Discovery Growth A | 427K | 0.39% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 395K | 0.36% | 0.00% | Sep 2026 |
| Fidelity Blue Chip Growth | 328K | 0.30% | 0.00% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 307K | 0.28% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 299K | 0.27% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 254K | 0.23% | 0.00% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 211K | 0.19% | 0.00% | Sep 2026 |
| Fidelity Advisor Health Care I | 208K | 0.19% | 0.00% | Sep 2026 |
| EQ/AB Small Cap Growth IB | 172K | 0.16% | 0.00% | Sep 2026 |
| MFS VIT New Discovery Init | 165K | 0.15% | 0.00% | Sep 2026 |
| Franklin Small Cap Growth Adv | 159K | 0.14% | 0.00% | Sep 2026 |
| T. Rowe Price US Smlr Coms Eq A | 146K | 0.13% | 0.00% | Sep 2026 |
| Principal SmallCap Growth I Instl | 135K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 126K | 0.11% | 0.00% | Sep 2026 |
ADARx Pharmaceuticals, Inc. Common Stock company profile
- Company name
- ADARx Pharmaceuticals, Inc. Common Stock
- Ticker
- ADRX.US
- Exchange
- USA Stocks
- Listed since
- Sep 25, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- December
- Address
- 5871 Oberlin Drive, San Diego, CA, United States, 92121
- Phone
- (877) 232-7974
- Website
- adarx.com
About ADARx Pharmaceuticals, Inc. Common Stock
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.
ADARx Pharmaceuticals, Inc. Common Stock management
7- Dr. Li Zhen Ph.D.Co-Founder, President, CEO & Director · born 1961
- Dr. A. Robert MacLeod Ph.D.Chief Scientific Officer · born 1967
- Mr. Ryan Fisk M.B.A.CFO & Chief Business Officer · born 1982
- Dr. Christopher Claeboe M.B.A., Ph.D.Senior Vice President of Operations
- Dr. Rui Zhu Ph.D.Chief Technology Officer · born 1983
- Mr. Jiang Bian J.D.VP & Head of Legal
- Mr. Robert AcklesChief People Officer · born 1965